Oncotarget

Research Papers:

NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells

Pan Jiang, Xiaoyue Wu, Xuemin Wang, Wenbin Huang and Qing Feng _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:43337-43351. https://doi.org/10.18632/oncotarget.9712

Metrics: PDF 5427 views  |   HTML 3464 views  |   ?  


Abstract

Pan Jiang1, Xiaoyue Wu1, Xuemin Wang2, Wenbin Huang3, Qing Feng1

1Department of Nutrition and Food Hygiene, Key Laboratory of Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China

2Beijing Research Institute for Nutritional Resources, Beijing, China

3Department of Pathology, Affiliated Nanjing First Hospital of Nanjing Medical University, Nanjing, China

Correspondence to:

Qing Feng, email: [email protected]

Keywords: cisplatin, lung cancer, hsa-mir-98-5p, CTR1, NEAT1

Received: February 02, 2016     Accepted: May 12, 2016     Published: May 30, 2016

ABSTRACT

Platinum-based drugs are the firstline of treatment for non-small cell lung cancer (NSCLC), but resistance to these drugs is a major obstacle to effective chemotherapy. Our previous study revealed that the green tea polyphenol, EGCG, induced cisplatin transporter CTR1 (copper transporter 1) and enhanced cisplatin sensitivity in ovarian cancer. In this study, we found that EGCG upregulated CTR1 and increased platinum accumulation in NSCLC (A549, H460 and H1299) cells, cDDP-resistant A549 cells and a nude mouse xenograft model. Cisplatin-induced inhibition of cell growth was enhanced by EGCG treatment in vitro and in vivo. MicroRNA hsa-mir-98-5p appears to suppress CTR1 gene expression, while long non-coding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) appears to enhance it. Bioinformatics analysis showed that hsa-mir-98-5p has specific complementary binding sites for NEAT1. In addition, hsa-mir-98-5p was predicted to be a putative CTR1 target. NEAT1 may act as a competing endogenous lncRNA to upregulate EGCG-induced CTR1 by sponging hsa-mir-98-5p in NSCLC. Our findings reveal a novel mechanism how NEAT1 upregulates EGCG-induced CTR1 and enhances cisplatin sensitivity in vitro and in vivo, and suggest EGCG could serve as an effective adjuvant chemotherapeutic in lung cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9712